Selective antisense compounds and uses thereof
The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
1. An oligomeric compound comprising a modified oligonucleotide having a modification motif comprising:
a 5′-region consisting of three linked 5′-region nucleosides, wherein the 5′-region has an ABB motif;
a 3′-region consisting of four linked 3′-region nucleosides, wherein the 3′-region has a BBAB motif; and
a central region between the 5′-region and the 3′-region consisting of 6-12 linked central region nucleosides, each independently selected from a nucleoside comprising a modified sugar moiety and a nucleoside comprising an unmodified deoxyribosyl sugar moiety, wherein the 5′-most central region nucleoside comprises an unmodified deoxyribosyl sugar moiety and the 3′-most central region nucleoside comprises an unmodified deoxyribosyl sugar moiety;
wherein each A is a nucleoside comprising a non-bicyclic modified sugar moiety, each B is a bicyclic nucleoside.
2. The oligomeric compound of claim 1 , wherein each B comprises a bicyclic sugar moiety independently selected from cEt, cMOE, LNA, α-LNA, ENA, and 2′-thio LNA.
3. The oligomeric compound of claim 2 , wherein each B comprises a bicyclic sugar moiety independently selected from cEt and LNA.
4. The oligomeric compound of claim 2 , wherein each B comprises a cEt sugar moiety.
5. The oligomeric compound of claim 1 , wherein each A comprises a non-bicyclic 2′-substituted sugar moiety.
6. The oligomeric compound of claim 5 , wherein each A is a nucleoside comprising a 2′-substituent independently selected from a halogen, OCH 3 , OCF 3 , OCH 2 CH 3 , OCH 2 CF 3 , OCH 2 —CH═CH 2 , O(CH 2 ) 2 —OCH 3 (MOE), O(CH 2 ) 2 —O(CH 2 ) 2 —N(CH 3 ) 2 , OCH 2 C(═O)—N(H)CH 3 , OCH 2 C(═O)—N(H)—(CH 2 ) 2 —N(CH 3 ) 2 , and OCH 2 —N(H)—C(═NH)NH 2 .
7. The oligomeric compound of claim 5 , wherein each A is a nucleoside comprising a 2′-substituent independently selected from F, OCH 3 , and O(CH 2 ) 2 —OCH 3 (MOE).
8. The oligomeric compound of claim 1 , wherein each A is a nucleoside comprising a 2′-O(CH 2 ) 2 —OCH 3 (MOE) substituent.
9. The oligomeric compound of claim 4 , wherein each A is a nucleoside comprising a 2′-O(CH 2 ) 2 —OCH 3 (MOE) substituent.
10. The oligomeric compound of claim 1 , wherein the central region consists of 6-10 linked nucleosides.
11. The oligomeric compound of claim 1 , wherein the central region consists of 7 linked nucleosides.
12. The oligomeric compound of claim 1 , wherein the central region consists of 8 linked nucleosides.
13. The oligomeric compound of claim 1 , wherein the central region consists of 9 linked nucleosides.
14. The oligomeric compound of claim 1 , wherein each central region nucleoside comprises an unmodified deoxyribosyl sugar moiety.
15. The oligomeric compound of claim 1 , wherein at least one central region nucleoside comprises a modified sugar moiety.
16. The oligomeric compound of claim 15 , wherein one central region nucleoside comprises a modified sugar moiety and each of the other central region nucleosides comprises an unmodified deoxyribosyl sugar moiety.
17. The oligomeric compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.
18. The oligomeric compound of claim 17 , wherein each internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage.
19. The oligomeric compound of claim 17 , wherein at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.
20. The oligomeric compound of claim 17 , wherein at least one modified internucleoside linkage is a methylphosphonate internucleoside linkage.